We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

44 hedge funds and large institutions have $6.07M invested in PDS Biotechnology in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.14% more ownership

Funds ownership: 11.95% → 16.09% (+4.1%)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

6% less funds holding

Funds holding: 47 → 44 (-3)

9% less capital invested

Capital invested by funds: $6.64M → $6.07M (-$572K)

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

Holders
44
Holders Change
-3
Holders Change %
-6.38%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.56M
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$95.9K
3
UBS Group
UBS Group
Switzerland
+$46.4K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$44.7K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$36.1K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$390K
2
IWA
Inspirion Wealth Advisors
Illinois
-$148K
3
Renaissance Technologies
Renaissance Technologies
New York
-$89.4K
4
Squarepoint
Squarepoint
New York
-$89.4K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$61K
Name Holding Trade Value Shares
Change 		Change in
Stake
Raymond James Financial
26
Raymond James Financial
Florida
$10.6K -$36 -40 -0.3%
WG
27
Wealth Group
North Carolina
$10K +$12.1K +13,399 New
GD
28
Grandfield & Dodd
New York
$7.7K – – –
DC
29
Davenport & Co
Virginia
$7.7K +$9.02K +10,000 New
Citigroup
30
Citigroup
New York
$7.23K +$8.45K +9,369 +39,038%
Wells Fargo
31
Wells Fargo
California
$4.1K – – –
Morgan Stanley
32
Morgan Stanley
New York
$3.79K -$3.01K -3,337 -40%
Group One Trading
33
Group One Trading
Illinois
$3.02K +$3.54K +3,922 New
CFD
34
Creative Financial Designs
Indiana
$2.31K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$1.71K +$2K +2,220 New
Jones Financial Companies
36
Jones Financial Companies
Missouri
$1.54K – – –
Bank of America
37
Bank of America
North Carolina
$791 -$8 -9 -0.9%
TC
38
Truvestments Capital
Florida
$504 – – –
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$499 -$440 -488 -43%
BWA
40
Basecamp Wealth Advisors
Washington
$290 +$340 +377 New
SS
41
SBI Securities
Japan
$84 -$1 -1 -0.9%
JP Morgan Chase
42
JP Morgan Chase
New York
$15 -$541 -600 -97%
Osaic Holdings
43
Osaic Holdings
Arizona
$13 – – –
Citadel Advisors
44
Citadel Advisors
Florida
– -$390K -386,430 Closed
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
– -$61K -61,793 Closed
Jane Street
46
Jane Street
New York
– -$36.9K -36,581 Closed
Dimensional Fund Advisors
47
Dimensional Fund Advisors
Texas
– -$18.6K -18,382 Closed
TSS
48
Two Sigma Securities
New York
– -$14.3K -14,149 Closed
Mercer Global Advisors
49
Mercer Global Advisors
Colorado
– -$12.6K -12,500 Closed
SWP
50
Stratos Wealth Partners
Ohio
– -$11.4K -11,303 Closed
1
2
3

PDSB Hedge Fund Activity: Q4 2025 in Review

44 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2025, worth a combined $6.07M — down 8.6% from $6.64M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PDSB and 10 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 11 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $2.56M. The largest seller was Citadel Advisors, exiting entirely with an estimated $390K sold.

  • 44 institutional investors held PDS Biotechnology (PDSB) as of Q4 2025, down from 47 in Q3 2025.
  • Funds reported $6.07M of PDS Biotechnology stock for Q4 2025, down 8.6% quarter-over-quarter.
  • 10 funds opened new PDS Biotechnology positions in Q4 2025 and 11 closed out, a net change of -1 holder.
  • The largest PDS Biotechnology buyer in Q4 2025 was Armistice Capital, an estimated $2.56M added.
  • The largest PDS Biotechnology seller in Q4 2025 was Citadel Advisors, an estimated $390K sold.

Based on aggregated 13F filings for Q4 2025.